The goal of the bioinformatics/biostatistics core is to address the bioinformatics, statistical and data management needs of the participating SPORE projects. To this end, the bioinformatics/biostatistics core will work in close collaboration with existing Yale informatics resources, projects and research groups. The core is also tightly integrated with the SPORE specimen resource core for the development of a tissue tracking and annotation system.
The specific aims of the bioinformatics/biostatistics core are 1) the bioinformatics and statistical analysis of SPORE project data and 2) the design, building and maintenance of a SPORE data management and analysis system (SPORE-DMAS). For 1), an important focus is the close interaction with the project investigators during the entire duration of the SPORE program. The core will provide continuous analysis services such as protocol design, data annotation and visualization. The analyses will chiefly focus on projects 1,2 and 4, which concern the elucidation of risk factors for early onset BCC patients, the detection of predictive epigenomic markers in metastatic melanoma cells, as well as establishing the serological profiles of melanoma patients. For 2), the core will design, build and maintain a SPORE data management and analysis system (SPORE-DMAS) for tracking of biological specimens, and processing of clinical and experimental data. The SPORE-DMAS will be tightly integrated into SPORE specimen resource core, and will handle the data management needs of the SPORE project members. The SPORE-DMAS will make extensive use of existing informatics systems at Yale University, and of resources from caBIG's Tissue Banks and Pathology Tools Workspace. The core will also be concerned with making data available according to the SPORE data and resource sharing plan.
|Ferrucci, Leah M; Cartmel, Brenda; Clare, Rachel A et al. (2018) Cross-sectional assessment of ultraviolet radiation-related behaviors among young people after a diagnosis of melanoma or basal cell carcinoma. J Am Acad Dermatol 79:149-152|
|Arbesman, Joshua; Ravichandran, Sairekha; Funchain, Pauline et al. (2018) Melanoma cases demonstrate increased carrier frequency of phenylketonuria/hyperphenylalanemia mutations. Pigment Cell Melanoma Res 31:529-533|
|Perry, Curtis J; Muñoz-Rojas, Andrés R; Meeth, Katrina M et al. (2018) Myeloid-targeted immunotherapies act in synergy to induce inflammation and antitumor immunity. J Exp Med 215:877-893|
|Liu, Xiaoni; Zhang, Shang-Min; McGeary, Meaghan K et al. (2018) KDM5B Promotes Drug Resistance by Regulating Melanoma Propagating Cell Subpopulations. Mol Cancer Ther :|
|Sulkowski, Parker L; Scanlon, Susan E; Oeck, Sebastian et al. (2018) PTEN Regulates Nonhomologous End Joining By Epigenetic Induction of NHEJ1/XLF. Mol Cancer Res 16:1241-1254|
|Chen, Ling; Azuma, Takeshi; Yu, Weiwei et al. (2018) B7-H1 maintains the polyclonal T cell response by protecting dendritic cells from cytotoxic T lymphocyte destruction. Proc Natl Acad Sci U S A 115:3126-3131|
|Krauthammer, Michael (2018) Unraveling the etiology of primary malignant melanoma of the esophagus. J Thorac Dis 10:S1074-S1075|
|Das, Rituparna; Bar, Noffar; Ferreira, Michelle et al. (2018) Early B cell changes predict autoimmunity following combination immune checkpoint blockade. J Clin Invest 128:715-720|
|Miller, Chad J; Muftuoglu, Yagmur; Turk, Benjamin E (2017) A high throughput assay to identify substrate-selective inhibitors of the ERK protein kinases. Biochem Pharmacol 142:39-45|
|Kluger, Harriet M; Zito, Christopher R; Turcu, Gabriela et al. (2017) PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors. Clin Cancer Res 23:4270-4279|
Showing the most recent 10 out of 172 publications